{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Number of patients who died due to transplant related toxicities","groups":[{"description":"All patients that received Basiliximab 20 mg monoclonal therapy","id":"OG000","title":"Basiliximab 20 mg"}],"paramType":"NUMBER","populationDescription":"Intent To Treat: All patients that received study drug","timeFrame":"up to 2 years after stem cell transplant","title":"Patients Who Experience Serious Transplant Related Toxicities as Evaluated by Bone Marrow Transplant-adjusted NCI Common Toxicity Criteria.","type":"SECONDARY","unitOfMeasure":"participants"}